ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells

• Published in: Leukemia Vol. 27; no. 6; pp. 1369 - 1380
• Main Authors: Chee, L C Y, Hendy, J, Purton, L E, McArthur, G A
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.06.2013
• Subjects: Acute myeloid leukemia; Acute promyeloid leukemia; Agonists; Agonists (Biochemistry); AKT protein; AML1 protein; Animal experimentation; Animal models; Animals; Bone marrow; Bone morphogenetic protein 2; Care and treatment; Cell differentiation; Cell self-renewal; Core Binding Factor Alpha 2 Subunit - genetics; Differentiation; Flow Cytometry; Gene expression; Genetic aspects; Hematopoietic stem cells; Isotypes; Leukemia; Mice; Mice, Inbred C57BL; Oncogene Proteins, Fusion - genetics; Osteoprogenitor cells; Phosphorylation; Physiological aspects; Progenitor cells; Promyeloid leukemia; Receptors, Retinoic Acid - agonists; Retinoic acid; Retinoic Acid Receptor alpha; Retinoic acid receptors; RUNX1 Translocation Partner 1 Protein; Selectivity; Stem cells; Tretinoin - pharmacology
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/leu.2012.362

All-trans retinoic acid (ATRA) is used successfully in the treatment of acute promyelocytic leukemia (APL). ATRA enhances hematopoietic stem cell self-renewal through retinoic acid receptor (RAR)γ activation while promoting differentiation of committed myeloid progenitors through RARα activation. Its lack of success in the treatment of non-APL acute myeloid leukemia (AML) may be related to ATRA's non-selectivity for the RARα and RARγ isotypes, and specific RARα activation may be more beneficial in promoting myeloid differentiation. To investigate this hypothesis, the effects of ATRA and the specific RARα agonist NRX195183 was assessed in AML1-ETO (AE)-expressing murine bone marrow (BM) progenitors. ATRA potentiated the in vitro clonogenicity of these cells while NRX195183 had the opposite effect. Morphological and flow cytometric analysis confirmed a predominantly immature myeloid population in the ATRA-treated AE cells while the NRX195183-treated cells demonstrated an increase in the mature myeloid population. Similarly, NRX195183 treatment promoted myeloid differentiation in an AE9a in vivo murine model. In the ATRA-treated AE cells, gene expression analyses revealed functional networks involving SERPINE1 and bone morphogenetic protein 2; AKT phosphorylation was upregulated. Collectively, these findings confirm the contrasting roles of specific RARα and RARγ activation in the clonogenicity and differentiation of AE cells with potential significant implications in the treatment of non-APL AML using a specific RARα agonist.